1 PF9404C is the S-S diesteroisomer of a novel blocker of beta adrenergic r
eceptors with vasodilatory properties. It causes a concentration-dependent
relaxation of rat aorta helical strips pre-contracted with 10(-6) M noradre
naline (NA; IC50 33 nM). It was equipotent to nitroglycerin (NTG; IC50 49 n
M), but much more potent than isosorbide dinitrate (ISD; ICS, 15,000 nM).
2 Oxyhaemoglobin (10 mu M) shifted to the right the concentration-response
curve for the relaxation induced by PF9404C (IC50 530 nM) or NTG (IC50 61 n
M).
3 Either methylene blue (MB) or ODQ (1 mu M each) largely prevented the vas
orelaxing responses to increasing concentrations of PF9404C or NTG.
4 In rat aorta smooth muscle cells, PF9404C increased the formation of cycl
ic GMP from 3 pmol mg(-1) protein in basal conditions, to 53 pmol mg(-1) pr
otein in 10 mu M PF9404C. Neither metoprolol nor carvedilol enhanced cyclic
GMP.
5 In the electrically driven guinea-pig left atrium, PF9404C blocked the in
otropic effects of isoprenaline in a concentration-dependent manner. Its IC
50 (30 nM) was similar to that for S-propranolol (22.4 nM) and lower than t
he IC(50)s for metoprolol (120 nM) and atenolol (192 nM). The beta-adrenerg
ic ligand (-)-[H-3]-CGP12177 (0.2 nM) was displaced from its binding to rat
brain membranes with K-i of 7 nM, 17 nM, 170 nM and 1.2 mu M respectively
for PF9404C, S(-)propranolol, metoprolol, and atenolol.
6 The data are consistent with the idea that the S-S diesteroisomer PF9404C
, is a potent vasorelaxing agent, as well as a blocker of cardiac beta adre
nergic receptors. The mechanism of its vasorelaxing effects involves the sl
ow generation of NO. This molecule can, therefore, exhibit antihypertensive
and cardioprotective actions through a double mechanism, NO donation and b
eta blockade.